| Code | CSB-RA707478MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Vopratelimab, targeting the Inducible T-cell CO-Stimulator (ICOS, CD278). ICOS is a critical co-stimulatory molecule expressed on activated T cells that plays a pivotal role in T-cell activation, differentiation, and effector function. Upon binding to its ligand ICOSL, ICOS enhances T-cell responses and promotes the development and function of follicular helper T cells and regulatory T cells. Dysregulation of ICOS signaling has been implicated in various immune-mediated conditions and represents an important checkpoint in cancer immunology, where ICOS-expressing tumor-infiltrating lymphocytes contribute to anti-tumor immunity.
Vopratelimab is an investigational agonistic antibody that stimulates ICOS signaling to enhance anti-tumor immune responses, currently under clinical evaluation for various solid tumors. This biosimilar antibody provides researchers with a valuable tool for investigating ICOS-mediated immune mechanisms, studying T-cell co-stimulation pathways, and exploring novel immunotherapeutic strategies in oncology and autoimmune disease models. It enables detailed characterization of ICOS function in immune regulation and tumor microenvironment dynamics.
There are currently no reviews for this product.